We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
MIV Therapeutics (MIVT) , a developer of next-generation drug-eluting coatings
that inhibit the rejection of implanted medical devices, has announced the successful
completion of pilot preclinical studies of hydroxyapatite (HAp) coated stents
in pig coronary arteries.
Dade Behring, a maker of blood-testing kits, has received FDA approval to use
its NT-proBNP test on the company's Stratus CS Acute Care Diagnostics System.
IDev Technologies has received 510(k) clearance from the FDA to market the AKonya
Eliminator Plus Mechanical Thrombectomy Device in the U.S. and has commercially
released the CE-Marked device into the European market, the company said.
Medtronic has announced results of the COMPASS-HF (Chronicle Offers Management
to Patients with Advanced Signs and Symptoms of Heart Failure) clinical trial
that were presented at the American College of Cardiology Annual Scientific
Session.
Abbott announced the availability of a fully automated
hepatitis C virus (HCV) test in the U.S. for its widely-used AxSYM automated
immunoassay instrument system.
Fisher Scientific International has signed a definitive agreement to sell Atos
Medical AB, a manufacturer of ear, nose and throat medical devices with 2004
sales totaling $35 million, to Nordic Capital for $110 million in cash.
Delphi Medical Systems, a subsidiary of Delphi, expanded its collaboration with
SRI International, a non-profit public benefit organization, to develop a patented,
respiratory care family of devices for use primarily at home and in alternate
sites.
Nanogen, developer of advanced diagnostic products, announced its subsidiary
SynX signed five new European distributors for its point-of-care products.
Cambridge Heart announced the completion of enrollment in the MASTER I Clinical
Trial (Microvolt T-Wave AlternanS TEsting for Risk Stratification of Post MI
Patients).
After the leaky mitral valves in their hearts were repaired nonsurgically with
a tiny, catheter-fed clip, nearly all -- over 90 percent -- of the patients whose
mitral regurgitation was significantly reduced one month after receiving the
clip maintained the reduction at six months.
Arcturus Bioscience, has announced that Antonius Schuh has been appointed chief
executive officer and will be elected a member of the company's board of directors.